Drug Trial Radar · NCT03574402
Phase II Umbrella Study Directed by Next Generation Sequencing
Last checked: Nov 20, 2026Latest source record: Dec 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
400
Planned (sponsor's estimate)
Start
Jul 9, 2018
Primary completion
Dec 30, 2022
Study completion Dec 30, 2024
Sponsor
- Lead sponsor
- Guangdong Association of Clinical TrialsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Chinese Thoracic Oncology Group
- First posted
- Jul 2, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II, umbrella trial study directed by next generation sequencing (NGS) works in Chinese patients with advanced stage NSCLC who never received any anti-tumor treatment. The purpose of this study is to evaluate efficacy of targeted therapies or immunotherapy to NSCLC patients whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
Avitinib MaleateDrug
300mg orally (PO) twice daily (BID) on day 1-28.
AfatinibDrug
40mg orally once a day, 28 days as one cycle.
CrizotinibDrug
250mg PO QD on days 1-28. 28 days as one cycle.
X-396Drug
225mg PO QD on days 1-28. 28 days as one cycle.
ChidamideDrug
30mg orally twice weekly, 28 days as one cycle.
Pyrotinib MaleateDrug
400mg PO QD on days 1-28. 28 days as one cycle.
AZD3759Drug
200mg PO BID on days 1-28. 28 days as one cycle.
PirotinibDrug
60mg PO QD/40mg PO BID on days 1-28. 28 days as one cycle.
NimotuzumabDrug
400mg, iv gtt. on day 1,8,15. 21 days as one cycle.
PemetrexedDrug
500mg/m\^2, iv gtt. Q3W. 21 days as one cycle.
CisplatinDrug
75mg/m\^2, iv gtt. Q3W on day1. 21 days as one cycle.
SintilimabDrug
200mg iv gtt. Q3W on day1. 21 days as one cycle.
GemcitabineDrug
1g/m\^2 iv gtt. on day1,8. 21 days as one cycle.
GemcitabineDrug
1.25g/m\^2 iv gtt. on day1,8. 21 days as one cycle.
CarboplatinDrug
AUC5 iv gtt. Q3W on day1. 21 days as one cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Response rate (RR)Time frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.